Evidence map›Paper›PMID 25360144›Full record

ArticleFrontiers in genetics2014

The fragile X syndrome-autism comorbidity: what do we really know?

Leonard Abbeduto, Andrea McDuffie, Angela John Thurman

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 3 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 3 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Expressive Language Sample Concordance With ADOS-2 Scores: Autism, Down Syndrome, Fragile X Syndrome.American journal on intellectual and developmental disabilities · 2026
    Article
  11. Article
  12. Screening of CGG Trinucleotide Repeats WithinJournal of the Korean Academy of Child and Adolescent Psychiatry · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Leonard AbbedutoMIND Institute, University of California, Davis , Sacramento, CA, USA ; Department of Psychiatry and Behavioral Sciences, University of California, Davis , Sacramento, CA, USA.
Andrea McDuffieMIND Institute, University of California, Davis , Sacramento, CA, USA ; Department of Psychiatry and Behavioral Sciences, University of California, Davis , Sacramento, CA, USA.
Angela John ThurmanMIND Institute, University of California, Davis , Sacramento, CA, USA ; Department of Psychiatry and Behavioral Sciences, University of California, Davis , Sacramento, CA, USA.
University of California, Davis · US

Funding

LINGUISTIC COMMUNICATION AND MENTAL RETARDATIONR01HD024356 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI ABBEDUTO, LEONARD J. · 1987 to 2022
$9.0M
Rodent Behavior CoreU54HD079125 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI OZONOFF, SALLY · 2013 to 2019
$8.5M
NICHD NIH HHS R01 HD024356NICHD NIH HHS U54 HD079125
6 · The paper itself

Abstract

Autism spectrum disorder (ASD) is a common comorbid condition in people with fragile X syndrome (FXS). It has been assumed that ASD symptoms reflect the same underlying psychological and neurobiological impairments in both FXS and non-syndromic ASD, which has led to the claim that targeted pharmaceutical treatments that are efficacious for core symptoms of FXS are likely to be beneficial for non-syndromic ASD as well. In contrast, we present evidence from a variety of sources suggesting that there are important differences in ASD symptoms, behavioral and psychiatric correlates, and developmental trajectories between individuals with comorbid FXS and ASD and those with non-syndromic ASD. We also present evidence suggesting that social impairments may not distinguish individuals with FXS with and without ASD. Finally, we present data that demonstrate that the neurobiological substrates of the behavioral impairments, including those reflecting core ASD symptoms, are different in FXS and non-syndromic ASD. Together, these data suggest that there are clinically important differences between FXS and non-syndromic ASD that are masked by reliance on the categorical diagnosis of ASD. We argue for use of a symptom-based approach in future research, including studies designed to evaluate treatment efficacy.

Indexed as

autism spectrum disordercomorbid conditionsfragile X syndromelanguage and communication impairmentspsychiatric conditions

Identifiers

PMID25360144
PMCPMC4199273
OpenAlexW2111988223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.